DA Davidson raised the firm’s price target on Vital Farms to $25 from $21 and keeps a Buy rating on the shares after its Q4 earnings beat. The company’s accelerated consumption is less about avian influenza and more about fundamentals, as industry supply appears stable, the analyst tells investors in a research note. Vital’s increased processing capacity is also supportive of expanded distribution breadth & depth, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VITL:
- Vital Farms price target raised to $26 from $22 at Lake Street
- Vital Farms price target raised to $18 from $16 at Goldman Sachs
- Vital Farms Reports Fourth Quarter and Fiscal Year 2023 Financial Results
- Vital Farms sees 2024 net revenue at least $552M, consensus $550.6M
- Vital Farms reports Q4 EPS 17c, consensus 9c